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Summary  The  proprotein  convertase  subtilisin/kexin  type  9  (PCSK9)  regulates  cholesterol
metabolism  mainly  by  targeting  the  low-density  lipoprotein  receptor  (LDLR)  for  degradation  in
the liver.  Gain-of-function  mutations  in  PCSK9  are  one  of  the  genetic  causes  of  autosomal  dom-
inant hypercholesterolaemia.  Conversely,  loss-of-function  mutations  are  associated  with  lower
concentrations  of  LDL  cholesterol  (LDL-C)  and  reduced  coronary  heart  disease.  As  these  loss-
of-function mutations  are  not  associated  with  apparent  deleterious  effects,  PCSK9  inhibition
is an  attractive  new  strategy  for  lowering  LDL-C  concentration.  Among  the  various  approaches
to PCSK9  inhibition,  human  data  are  only  available  for  inhibition  of  PCSK9  binding  to  LDLR  by
monoclonal  antibodies.  In  phase  II  studies,  the  two  most  advanced  monoclonal  antibodies  in
development  (alirocumab  and  evolocumab)  decreased  atherogenic  lipoproteins  very  effectively
and were  well  tolerated.  A  dramatic  decrease  in  LDL-C  up  to  70%  can  be  obtained  with  the  most
efﬁcacious doses.  Efﬁcacy  has  been  evaluated  so  far  in  addition  to  statins  in  hypercholestero-
laemic patients  with  or  without  familial  hypercholesterolaemia,  in  patients  with  intolerance
to statin  therapy  and  in  monotherapy.  Large  phase  III  programmes  are  ongoing  to  evaluate  the
long-term  efﬁcacy  and  safety  of  these  very  promising  new  agents.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.Abbreviations: ADH, autosomal dominant hypercholesterolaemia; apo, apolipoprotein; CHD, coronary heart disease; FH, familial hyper-
holesterolaemia; GOF, gain-of-function; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LDLR,
ow-density lipoprotein receptor; LOF, loss-of-function; Lp(a), lipoprotein (a); mAbs, monoclonal antibodies; PCSK9, proprotein convertase
ubtilisin/kexin type 9; Q2W, every 2 weeks; Q4W, every 4 weeks; siRNA, small interfering RNA; SREBP2, sterol-responsive element-binding
rotein 2.
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Résumé  PCSK9  ou  proprotein  convertase  subtilisin/kexin  type  9  est  une  protéine  clé  dans  la
régulation  du  métabolisme  du  cholestérol  qui  agit  principalement  en  augmentant  la  dégradation
du récepteur  des  lipoprotéines  de  basse  densité  (LDLR)  dans  le  foie.  Des  mutations  « gain-de-
fonction » de  PCSK9  sont  l’une  des  causes  génétiques  de  l’hypercholestérolémie  autosomique
dominante.  À  l’opposé,  des  mutations  « perte-de-fonction  » ont  été  associées  avec  des  taux  bas
de LDL-cholestérol  (LDL-C)  et  une  réduction  du  risque  de  maladie  coronarienne.  Comme  ces
mutations « perte-de-fonction  » n’induisent  pas  d’effets  délétères,  l’inhibition  de  PCSK9  est  une
nouvelle stratégie  intéressante  pour  abaisser  les  taux  plasmatiques  de  LDL-C.  Parmi  les  diverses
approches pour  inhiber  PCSK9,  des  données  humaines  sont  seulement  disponibles  pour  l’instant
avec des  anticorps  monoclonaux  qui  inhibent  la  liaison  de  PCSK9  aux  LDLR.  Dans  les  études  de
phase II,  les  deux  anticorps  monoclonaux  les  plus  avancés  dans  le  développement  (alirocumab
et évolocumab)  se  sont  révélés  très  efﬁcaces  pour  diminuer  les  lipoprotéines  athérogènes  et  ont
été bien  tolérés.  Une  diminution  majeure  du  LDL-C  jusqu’à  70  %  a  été  observée  avec  les  doses  les
plus efﬁcaces.  L’efﬁcacité  a  été  évaluée  jusqu’alors  en  addition  aux  statines  chez  des  patients
hypercholestérolémiques  avec  ou  sans  hypercholestérolémie  familiale,  chez  des  patients  avec
intolérance  à  un  traitement  par  statine,  et  en  monothérapie.  De  larges  programmes  de  phase
III sont  en  cours  pour  évaluer  l’efﬁcacité  et  la  sécurité  d’emploi  à  long  terme  de  ces  nouveaux
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© 2013  Elsevier  Masson  SAS.
Background
High  concentrations  of  low-density  lipoprotein  cholesterol
(LDL-C)  have  consistently  been  associated  with  an  increased
risk  of  atherosclerotic  cardiovascular  disease,  particularly
coronary  heart  disease  (CHD).  Low-density  lipoprotein  (LDL)
particles  are  removed  from  the  circulation  mainly  by  hepatic
uptake  via  the  LDL  receptor  (LDLR).  LDL  binds  to  the  LDLR
and  the  LDL/LDLR  complex  is  internalized  into  clathrin-
coated  vesicles  by  endocytosis.  Then,  LDL  is  separated  from
its  receptor  in  the  endosomes  and  the  LDLR  is  recycled  for
reuse.  At  the  same  time,  LDL  is  degraded  (Fig.  1a).
Both  environmental  and  genetic  factors  regulate  plasma
concentrations  of  LDL-C.  Among  genetic  causes,  autosomal
dominant  hypercholesterolaemia  (ADH)  is  associated  with
elevated  LDL-C  concentration  and  premature  cardiovascular
disease.  In  the  majority  of  the  cases,  familial  hypercholes-
terolaemia  (FH)  is  related  to  mutations  in  the  LDLR  itself.
A  second  and  less  frequent  form  of  FH  is  caused  by  muta-
tions  in  the  ligand-binding  domain  of  apolipoprotein  (apo)
B100,  the  protein  component  of  LDL  that  interacts  with  the
LDLR  [1].  The  identiﬁcation  of  a  third  gene  associated  with
FH,  encoding  proprotein  convertase  subtilisin/kexin  type  9
(PCSK9),  has  generated  intensive  research  into  PCSK9,  mak-
ing  this  protein  a  key  regulator  for  LDLR  activity  and  an
attractive  target  for  the  treatment  of  hypercholesterolae-
mia  [2—5].
The discovery of PSCK9
In  2003,  Seidah  et  al.  identiﬁed  the  ninth  member  of  the  pro-
protein  convertase  family,  PCSK9  [6].  In  the  same  year,  the
involvement  of  PCSK9  in  regulating  cholesterol  metabolism
became  evident,  with  the  identiﬁcation  of  two  gain-of-
function  (GOF)  mutations  in  PCSK9,  in  two  French  families
with  a  clinical  diagnosis  of  ADH  and  no  detectable  muta-
tions  in  LDLR  or  apoB100  genes  [7].  Since  this  ﬁrst  report,
several  other  GOF  mutations  have  been  reported  [8],  asso-
ciated  with  mild  to  severe  hypercholesterolaemia  and  an
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ncreased  risk  of  CHD  [9].  However,  GOF  mutations  in  PCSK9
re  relatively  rare  and  account  for  a  small  percentage  of
atients  with  ADH  [1].
Conversely,  the  genetic  evidence  suggesting  a  potential
ole  for  PCSK9  inhibition  in  decreasing  LDL-C  concentra-
ion  came  from  the  identiﬁcation  of  loss-of-function  (LOF)
utations  and  common  polymorphisms  associated  with
ower  LDL-C  concentrations.  The  ﬁrst  LOF  mutations  were
escribed  in  2005  [10]  and  the  effect  of  lifelong  reductions
n  LDL-C  induced  by  these  LOF  mutations  was  examined  in
he  atherosclerosis  risk  in  communities  study  [11]:  the  LOF
utations  Y142X  and  C679X  in  African  Americans  were  asso-
iated  with  a  28%  reduction  in  LDL-C  and  an  88%  reduction
n  the  risk  of  CHD,  whereas  the  R46L  mutation  in  Caucasians
as  associated  with  a  15%  reduction  in  LDL-C  and  a  47%
eduction  in  the  risk  of  CHD  [11].
Numerous  other  LOF  mutations  or  polymorphisms  asso-
iated  with  decreased  LDL-C  concentrations  have  been
dentiﬁed  [8].  The  association  between  the  R46L  mutation
nd  the  risk  of  CHD  has  been  extensively  evaluated  in  three
ndependent  Danish  studies  [12].  In  meta-analyses,  R46L
arriers  had  a  12%  reduction  in  LDL-C  and  a  28%  reduction  in
HD  risk  [12].  The  fact  that  CHD  risk  reduction  was  consid-
rably  larger  than  predicted  with  similar  LDL-C  reductions
n  statin  trials  [13]  could  be  explained  by  the  effect  of  long-
erm  exposure  to  lower  LDL-C  beginning  early  in  life.  This
s  also  in  agreement  with  the  results  of  a  Mendelian  ran-
omization  analysis,  in  which  long-term  exposure  to  lower
DL-C  was  associated  with  a  three-fold  greater  reduction  in
HD  risk  than  that  observed  during  treatment  with  a  statin
tarted  later  in  life  [14].
tructure and biosynthesis of PCSK9
he  human  PCSK9  gene  located  on  chromosome  1p32.3
ncodes  a  692-amino  acid  inactive  glycoprotein.  PCSK9
s  expressed  in  several  organs,  particularly  the  liver  and
lso  the  intestine  and  the  kidney  [5].  The  692-amino  acid
reproPCSK9  undergoes  signal  peptidase  cleavage  (domain
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Figure 1. Role of PCSK9 in the regulation of the hepatocyte LDLR activity: a: synthesis and recycling of LDLR; b: synthesis, secretion of
PCSK9 and effect on LDLR (PCSK9 binds to LDLR and, upon internalization, directs LDLR to lysosomal degradation, decreasing the number
of LDLRs at the cell surface); c: AMG145) mechanisms of action of statins and mAb against PCSK9 (statin therapy via SERBP2 activation,
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—30),  then  autocatalytic  cleavage  in  the  endoplasmic  reti-
ulum  into  two  products:  the  prodomain  and  the  mature
CSK9  containing  the  catalytic  domain  and  the  C-terminal
omain.  Cleavage  of  the  prodomain  is  required  for  the
aturation  and  secretion  of  PCSK9.  Indeed,  a  recent  LOF
utation  due  to  an  amino  acid  substitution  within  the  cleav-
ge  site  prevents  autocatalytic  processing  and,  by  inhibiting
CSK9  secretion,  is  associated  with  a  48%  reduction  in  LDL-C
oncentration  [15].
After  cleavage,  the  prodomain  or  prosegment  remains
ssociated  by  hydrogen  bonds  with  the  mature  active  form
nd  the  protein  is  ﬁnally  secreted  as  an  inactive  dimer
omplex  (Fig.  1b).  Recent  reviews  have  examined  the  role
f  this  complex  in  preventing  the  access  of  other  poten-
ial  substrates  to  the  catalytic  domain  of  PCSK9  [16,17].
he  activity  of  PCSK9  in  promoting  LDLR  degradation  seems
b
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cSK9 to the LDLR/LDL complex).
ndependent  of  its  catalytic  activity.  The  catalytic  domain
f  mature  PCSK9  binds  to  the  ﬁrst  epidermal  growth  factor-
ike  repeat  A  domain  of  the  LDLR,  while  the  C-terminal
omain  binds  to  cell  surface  proteins,  including  Annexin
2.
unctions of PCSK9
ole in the regulation of LDL-C concentration
he  major  function  of  PCSK9  is  the  degradation  of  the  LDLR
y  complex  mechanisms  [4,5,16]: PCSK9  directly  interacts
ith  the  LDLR  both  within  the  cell  and  at  the  surface  of
he  plasma  membrane  [5,8,16]. However,  evidence  indi-
ates  that  PCSK9  acts  on  the  LDLR  primarily  as  a  secreted
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factor  and  promotes  the  reduction  of  LDLR  protein  concen-
trations,  mainly  in  the  liver.  LDLR  protein  concentrations  are
increased  in  the  liver  of  PCSK9  knockout  mice  [18].
Secreted  PCSK9  binds  to  the  LDLR  in  a  complex  with  its
prosegment  and  is  subsequently  internalized  together  with
the  LDLR.  The  binding  of  PCSK9  to  LDLR  induces  modiﬁcation
of  LDLR  conformation,  avoiding  normal  recycling  of  LDLR  to
the  plasma  membrane  and  enhancing  the  LDLR  lysosomal
degradation  [19]  (Fig.  1b).
As  a  result,  LDLR  represents  the  main  route  of  elimination
of  PCSK9  [20].  However,  the  mature  secreted  PCSK9  can  be
inactivated  through  cleavage  by  other  proprotein  conver-
tases,  particularly  furin.  The  mature  active  form  and  the
inactive  form  of  PCSK9  circulate  in  the  bloodstream.
Other functions of PCSK9
Although  PCSK9  is  a  key  player  in  cholesterol  homeostasis
through  the  regulation  of  LDLR  concentrations,  data  suggest
a  role  in  triglyceride  metabolism  and  triglyceride  accumula-
tion  in  visceral  adipose  tissue  [21].  The  function  of  PCSK9
in  the  intestine  is  not  well  known.  It  has  been  recently
reported  that  PCSK9  can  enhance  chylomicron  secretion  and
participate  in  the  control  of  enterocyte  cholesterol  balance
[22].
Beyond  effects  on  lipid  metabolism,  animal  data  also
suggest  a  role  for  PCSK9  in  glucose  homeostasis  [23],  liver
regeneration  and  susceptibility  to  hepatitis  C  virus  infec-
tion  [2,17].  Although  unexpected  adverse  effects  cannot  be
excluded  during  PCSK9  inhibition,  genetic  variants  of  PCSK9
have  given  reassuring  information.  One  of  the  most  strik-
ing  examples  is  that  of  a  woman  who  carries  two  mutations
in  PCSK9  with  no  detectable  circulating  PCSK9,  an  LDL-C
concentration  of  14  mg/dL  and  normal  hepatic,  neuronal  and
renal  functions  [24].
Recently,  it  has  been  reported  that  absence  of  PCSK9  can
be  protective  against  melanoma  invasion  in  mouse  liver  [25],
suggesting  that  a  PCSK9  inhibitor  may  be  also  useful  in  ther-
apies  against  cancer  metastasis.  However,  there  is  a large
need  for  human  data  and,  until  now,  PCSK9  inhibitors  have
been  developed  to  treat  hypercholesterolaemia  and  prevent
atherosclerosis.
PCSK9 and atherosclerosis in animal
models
In  mice  lacking  PCSK9,  the  accumulation  of  cholesteryl
esters  in  aortas  was  markedly  reduced.  By  comparison,  over-
expression  of  PCSK9  induced  an  excess  of  atherosclerosis
[26].  But  in  LDLR-deﬁcient  mice  lacking  or  overexpress-
ing  PCSK9,  no  signiﬁcant  differences  were  observed  in
cholesteryl  ester  accumulation  and  plaque  size,  strongly
suggesting  that  the  process  by  which  PCSK9  enhances
atherosclerosis  is  primarily  mediated  through  its  action  on
the  LDLR  [26].Cloned  minipigs  created  by  transposition  of  a  human
PCSK9  GOF  mutant  —  a  model  for  FH  —  had  a  signiﬁcant
increase  in  aortic  atherosclerosis  compared  with  wild-type
minipigs  [27].
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egulation of PCSK9 plasma
oncentrations
CSK9  gene  expression  is  mainly  modulated  by  intracellu-
ar  cholesterol  concentrations  and  consequent  activation  of
he  transcription  factor  sterol-responsive  element-binding
rotein  2  (SREBP2)  [18], similarly  to  other  genes  involved
n  cholesterol  homeostasis,  such  as  LDLR.  This  concomitant
egulation  of  both  PCSK9  and  LDLR  by  cholesterol  via  SREBP2
elps  to  explain  the  ‘paradoxical  effect’  of  statin  therapy
2]: statins  not  only  upregulate  expression  of  the  LDLR,
ut  also  expression  of  PCSK9,  potentially  limiting  the  phar-
acological  effect  of  reducing  LDL-C  concentration  [28,29]
Fig.  1c).  Statin  administration  to  PCSK9  knockout  mice
nhanced  LDL  clearance  from  plasma  [18].  These  data  sup-
ort  PCSK9  inhibition  as  a  very  attractive  target  for  lowering
DL-C  and  enhancing  the  efﬁcacy  of  statin  treatment.
trategies for PCSK9 inhibition
everal  therapeutic  approaches  to  the  inhibition  of  PCSK9
ave  been  proposed  [30],  including:  inhibition  of  PCSK9
ynthesis  by  gene  silencing  agents,  such  as  antisense
ligonucleotides  or  small  interfering  RNA  (siRNA);  inhibi-
ion  of  PCSK9  binding  to  LDLR  by  monoclonal  antibodies
mAbs),  small  peptides  or  adnectins;  and  inhibition  of  PCSK9
utocatalytic  processing  by  small  molecule  inhibitors.  These
trategies,  targeting  either  extracellular  or  intracellular
CSK9,  have  been  extensively  described  in  recent  reviews
3—5,31].
Preclinical  studies  on  inhibition  of  PCSK9  synthesis  by
ntisense  oligonucleotides  were  promising,  but  the  devel-
pment  of  two  antisense  oligonucleotides  by  BMS/ISIS
BMS-84421)  and  Santaris  Pharma  (SPC5001)  was  stopped
n  phase  I [3,31].  siRNA  is  another  approach  [32,33]:  in  a
hase  I  trial  of  ALN-PCS  —  an  siRNA  developed  by  Alnylam
harmaceuticals  —  a  dose-dependent  reduction  in  LDL-C  was
bserved,  with  a  41%  reduction  at  day  4  with  the  high-
st  dose,  associated  with  a  68%  reduction  in  plasma  PCSK9
oncentrations  [31,34].  Inhibition  of  PCSK9  binding  to  LDLR
y  small  peptide  inhibitors  such  as  SX-PCK9  (Serometrix,
ast  Syracuse,  NY,  USA)  or  adnectins  such  as  BMS-962476
BMS/Adnexus,  Waltham,  MA,  USA)  are  in  preclinical  devel-
pment  or  phase  I  [3,31].  On  the  basis  of  the  discovery
f  an  LOF  mutation  in  the  autocatalytic  cleavage  site  of
CSK9  [15],  inhibition  of  PCSK9  autocatalytic  processing  is
he  approach  chosen  by  Cadila  Healthcare  and  Shifa  Biomed-
cal  [3,5], with  molecules  in  preclinical  development  phase.
inally,  mAbs  are  currently  the  most  advanced  approach  in
erms  of  clinical  development,  with  published  phase  I  and
hase  II  human  trials  (Fig.  1c).
fﬁcacy of monoclonal antibodies
argeting PCSK9everal  mAbs  targeting  PCSK9  have  been  tested  in  preclin-
cal  studies  to  assess  their  disruption  of  the  PCSK9-LDLR
nteraction  or  inhibition  of  PCSK9  internalization  [3].  Human
ata  are  available  for  three  of  these  mAbs:  SAR236553/
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EGN727  (alirocumab)  and  AMG145  (evolocumab),  two  fully
uman  mAbs  developed  by  Sanoﬁ/Regeneron  and  Amgen,
espectively;  and  RN316/PF04950615,  a  humanized  mAb
eveloped  by  Pﬁzer/Rinat.
lirocumab (SAR236553/REGN727)
hree  phase  I  studies  of  alirocumab  have  been  performed,
wo  in  healthy  volunteers  and  one  in  patients  with  hypercho-
esterolaemia  [35].  In  the  two  single  ascending-dose  studies,
lirocumab  reduced  LDL-C  in  a  dose-dependent  manner
y  28—65%  when  given  intravenously  (0.3—12.0  mg/kg)  and
y  32—46%  when  given  subcutaneously  (50—250  mg).  In
he  third  placebo-controlled  multiple-dose  trial,  alirocumab
as  administered  subcutaneously  at  doses  of  50,  100
r  150  mg  in  adults  receiving  atorvastatin  with  LDL-
 >  100  mg/dL  and  at  the  150  mg  dose  in  adults  on  diet  alone
ith  LDL-C  >  130  mg/dL.  Alirocumab  signiﬁcantly  reduced
DL-C  by  38—65%  in  patients  taking  atorvastatin  and  by
7%  in  patients  not  taking  atorvastatin.  Alirocumab  induced
 maximum  lowering  of  LDL-C  within  2  weeks.  It  seems
hat  the  duration  of  action  is  longer  in  subjects  who  are
ot  treated  with  atorvastatin,  suggesting  that  the  statin-
timulated  production  of  PCSK9  might  affect  the  duration
f  action  of  therapeutic  mAbs.
The  efﬁcacy  of  alirocumab  administered  subcutaneously
as  examined  in  three  phase  II  randomized  double-blind
lacebo-controlled  trials  [36—38].  The  efﬁcacy  on  athero-
enic  lipid  variables  observed  with  the  most  efﬁcacious  dose
s  indicated  in  Table  1.
In  77  heterozygous  FH  patients  on  stable  statin  therapy
with  or  without  ezetimibe)  and  LDL-C  ≥  100  mg/dL  random-
zed  into  ﬁve  study  groups  (placebo,  alirocumab  150  mg
very  4  weeks  [Q4W],  200  mg  Q4W,  300  mg  Q4W  and  150  mg
very  2  weeks  [Q2W]  [38]),  alirocumab  dose  dependently
educed  LDL-C  by  29—43%  for  150—300  mg  injected  Q4W
nd  by  68%  for  150  mg  injected  Q2  W.  With  the  150  mg  Q2W
ose  regimen,  more  than  80%  of  patients  achieved  an  LDL-C
oncentration  <  70  mg/dL.  In  addition,  the  150  mg  Q2W  dose
howed  signiﬁcant  decreases  in  apoB  and  non-high-density
ipoprotein  cholesterol  (non-HDL-C;  Table  1)  and  increases
n  HDL-C  (+6.5%  versus  baseline)  and  apoAI  (+8.8%  versus
aseline).
In  the  second  phase  II  trial,  a  12-week  study  of
83  patients  with  LDL-C  ≥  100  mg/dL  on  stable-dose  ator-
astatin  10,  20  or  40  mg  [36],  dose-dependent  and
egimen-dependent  reductions  in  LDL-C  were  observed:  the
ose  of  150  mg  Q2  W  was  found  to  be  the  most  effective
72%  reduction  in  LDL-C)  and  patients  receiving  100  and
50  mg  Q2W  had  greater  reductions  in  LDL-C  than  those
eceiving  200  and  300  mg  Q4W.  LDL-C  reductions  were  unaf-
ected  by  atorvastatin  dose.  With  the  dose  of  150  mg  Q2W,
poB,  non-HDL-C  and  lipoprotein  (a)  (Lp[a])  were  also  signif-
cantly  reduced  (Table  1)  and  all  patients  receiving  this  dose
chieved  targets  of  <  70  mg/dL,  <  80  mg/dL  and  <  100  mg/dL
or  LDL-C,  apoB  and  non-HDL-C,  respectively  [36].
In  the  last  phase  II  trial  [37],  92  patients  with  LDL-
 ≥  100  mg/dL  on  atorvastatin  10  mg  were  randomized  to
eceived  8  weeks  of  treatment  with  atorvastatin  80  mg
lus  alirocumab  150  mg  Q2W,  atorvastatin  10  mg  plus
lirocumab  150  mg  Q2W  or  atorvastatin  80  mg  plus  placebo
2W.  Adding  alirocumab  to  either  atorvastatin  80  mg  or
L
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torvastatin  10  mg  resulted  in  a  signiﬁcantly  greater  LDL-
 reduction  than  that  attained  with  atorvastatin  80  mg
lone.  Interestingly,  the  complementary  LDL-C  reduction
as  not  signiﬁcantly  different  between  the  groups  receiv-
ng  alirocumab  added  to  atorvastatin  80  or  10  mg.  All  the
atients  assigned  to  alirocumab,  compared  with  52%  in  the
roup  receiving  atorvastatin  80  mg  plus  placebo,  achieved
he  target  LDL-C  <  100  mg/dL.  Alirocumab  also  induced  sig-
iﬁcant  decreases  in  ApoB,  non-HDL-C  and  Lp(a)  (Table  1).
volocumab (AMG145)
wo  phase  I  studies  have  been  published  [39].  The  phase
a  study  is  a  single  ascending  subcutaneous  or  intravenous
ose  in  healthy  subjects.  Single  doses  (7—420  mg  admin-
stered  subcutaneously;  or  21  mg  or  420  mg  administered
ntravenously  in  a  1-hour  infusion)  of  evolocumab  induced
ose-dependent  reductions  in  LDL-C  by  up  to  64%  com-
ared  with  placebo.  The  phase  Ib  study  enrolled  seven
ypercholesterolaemic  cohorts  of  subjects  receiving  stable
tatin  therapy  (ﬁve  cohorts  receiving  low-to-moderate  statin
oses,  one  receiving  high-dose  statins  and  one  with  het-
rozygous  FH)  in  multiple  ascending  subcutaneous  doses
ith  different  dosing  intervals  (1—4  weeks).  Evolocumab
educed  mean  LDL-C  concentrations  by  up  to  75%  versus
lacebo  at  the  end  of  the  dosing  interval.
The  efﬁcacy  of  evolocumab  administered  subcutaneously
as  evaluated  in  four  12-week  phase  II  randomized  placebo-
ontrolled  (or  ezetimibe-controlled)  trials  [40—43].  The
ain  efﬁcacy  results  for  atherogenic  lipid  variables  obtained
ith  the  most  efﬁcacious  doses  are  summarized  in  Table  1.
In  167  heterozygous  FH  patients  on  stable  statin  therapy
with  or  without  ezetimibe)  and  LDL-C  ≥  100  mg/dL  random-
zed  to  evolocumab  350  mg  Q4W,  420  mg  Q4W  or  placebo,
volocumab  decreased  LDL-C  by  43.8%  in  the  350  mg  group
nd  56.4%  in  the  420  mg  group  (versus  placebo)  [40].  Signiﬁ-
ant  reductions  were  also  observed  for  apoB,  non-HDL-C  and
p(a)  concentrations  (Table  1).  Seventy  per  cent  of  patients
eceiving  350  mg  and  89%  of  those  receiving  420  mg  achieved
DL-C  <  100  mg/dL;  44%  and  65%  achieved  LDL-C  <  70  mg/dL.
he  results  obtained  with  both  alirocumab  and  evolocumab
n  FH  are  impressive,  taking  into  account  the  difﬁculty  in
eaching  LDL-C  goals  for  this  category  of  patients  [44].
In  the  LAPLACE-TIMI57  trial  [40],  631  patients  with  LDL-
 ≥  85  mg/dL  on  stable  statin  therapy  (with  or  without
zetimibe)  were  randomized  into  eight  groups:  six  treat-
ent  arms  with  evolocumab  at  70,  105  and  140  mg  Q2W,
r  evolocumab  at  280,  350  or  420  mg  Q4W;  and  two  con-
rol  groups  receiving  placebo  Q2W  or  Q4W.  Evolocumab
nduced  dose-dependent  signiﬁcant  reductions  in  LDL-C
41.8—66.1%  with  Q2W  regimen  and  41.8—50.3%  with  Q4W
egimen).  The  effects  on  other  atherogenic  lipoproteins
bserved  with  the  most  efﬁcacious  doses  (140  mg  Q2W
nd  420  mg  Q4W)  are  listed  in  Table  1.  Overall,  93.5%
f  patients  receiving  evolocumab  140  mg  Q2W  and  71.8%
f  patients  receiving  evolocumab  420  mg  Q4W  achieved
he  target  LDL-C  <  70  mg/dL.  In  a  complementary  analysis
f  LAPLACE-TIMI57  trial,  evolocumab  signiﬁcantly  reduced
p(a)  by  up  to  32%  [45].
The  GAUSS  trial  investigated  the  efﬁcacy  and  safety
f  evolocumab  in  160  statin-intolerant  patients  [43].
reatment  arms  included  evolocumab  at  280  mg,  350  mg
PCSK9
 as
 a
 therapeutic
 target
 
63
Table  1 Efﬁcacy  of  alirocumab  150  mg  Q2W  and  evolocumab  140  mg  Q2W  or  420  mg  Q4W  monoclonal  antibodies  to  PCSK9  on  atherogenic  plasma  lipid  and  lipoprotein
concentrations:  data  from  phase  2  clinical  trialsa.
Study  population Trial Drug  LDL-C
(%)
ApoB
(%)
Non-HDL-C  (%) Lp(a)
(%)
Heterozygous  FH RUTHERFORD  [40] AMG  420  mg  Q4W —56.4c —46.2c —53.5c —31.5c
Stein  et  al.  [36] SAR  150  mg  Q2W —57.3d —43.8d —46.6d —19.5
Patients  on  stable
statin  therapy
(±  ezetimibe)
LAPLACE-TIMI57  [41,45] AMG  140  mg  Q2W
AMG  420  mg  Q4W
—66.1d
—50.3d
—56.4d
—42.0d
—61.4d
—47.6d
—32.3c
—23.1c
Mc  Kenney  et  al.  [37] SAR  150  mg  Q2W —67.3d —58.3d —60.3d —28.6d
Roth  et  al.  [38]b SAR  150  mg  Q2W —66.2g —54.4g —58.3g —34.7g
Statin  intolerance GAUSS  [42]b AMG  420  mg  Q4W
AMG  420  mg  Q4W  +  EZE  10  mg
daily
—50.7e
—63.0e
—42.1e
—49.1e
—48.6e
—59.8e
—23.6f
—29.1e
Monotherapy  MENDEL  [43] AMG  140  mg  Q2W
AMG  420  mg  Q4W
—47.2d
—52.5d
—44.2d
—42.5d
—45.2d
—47.1 d
—29.3d
—29.2d
AMG: AMG145or evolocumab; ApoB: apolipoprotein B; EZE: ezetimibe; Lp(a): lipoprotein(a); Q2W: every 2 weeks; Q4W: every 4 weeks; SAR: SAR236553/REG727 or alirocumab.
a Data expressed as % change versus placebo (except as indicated).
b % change versus baseline.
c P < 0.001 versus baseline.
d P < 0.0001 versus baseline.
e P < 0.001 versus ezetimibe + placebo.
f P = 0.001 versus ezetimibe + placebo.
g P < 0.001 versus atorvastatin 80 mg + placebo.
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nd  420  mg  Q4W;  a  combined  treatment  group  was  given
volocumab  at  420  mg  Q4W  plus  ezetimibe  10  mg;  and  a
ontrol  group  received  placebo  subcutaneously  Q4W  plus
zetimibe  10  mg.  Versus  baseline,  evolocumab  induced  a
igniﬁcant  dose-dependent  decrease  in  LDL-C  from  40.8%
o  50.7%.  Furthermore,  the  combination  of  evolocumab  and
zetimibe  induced  an  almost  additive  63%  reduction  in  LDL-
.
The  last  phase  II  study  (MENDEL)  was  a  monotherapy
rial  evaluating  the  efﬁcacy  of  evolocumab  in  406  patients
ith  LDL-C  ≥  100  mg/dL  [41].  The  treatment  groups  were
dentical  to  those  for  LAPLACE-TIMI57,  with  a  complemen-
ary  group  receiving  ezetimibe  10  mg.  The  dose-dependent
eductions  in  LDL-C  (37.3—47.2%  with  AMG  Q2W  and
3.6—52.5%  with  AMG  Q4W)  appeared  similar  to  those
bserved  in  the  LAPLACE-TIMI57  trial  with  the  Q4W  regimen,
ut  smaller  than  those  observed  with  the  Q2W  regimen.
hese  data  suggest  that  the  Q4W  regimen  could  be  recom-
ended  without  statin  therapy  and  raises  the  question  of
he  best  regimen  for  those  on  statin  therapy.
Finally,  the  efﬁcacy  of  evolocumab  in  the  rare  popula-
ion  of  homozygous  FH  patients  has  been  tested  in  a  pilot
tudy  conducted  in  eight  patients  (two  receptor  negative
nd  six  receptor  defective).  Evolocumab  420  mg  Q2W  and
4W  decreased  LDL-C  by  26.3  and  19.3%,  respectively,  in
eceptor-defective  patients,  with  no  reduction  in  receptor-
egative  patients  [46].  These  preliminary  results  need  to  be
onﬁrmed  in  a  larger  trial.
N316/PF04950615
N316,  a  humanized  mAb  with  a  pH-sensitive  binding  to  the
CSK9  domain  that  interacts  with  the  LDLR-EGFA  domain,
as  developed  to  obtain  longer  serum  half-life  and  duration
or  the  LDL-C  decrease  in  mice  and  monkeys  [47]. In  phase
 studies,  RN316  lowered  LDL-C  in  hypercholesterolaemic
ubjects  treated  with  single  intravenous  and  subcutaneous
oses,  both  as  monotherapy  and  when  added  to  atorvas-
atin  [48].  In  phase  II  trials,  LDL-C  concentrations  were
igniﬁcantly  reduced  with  3.0  and  6.0  mg/kg  doses  of  RN316
dministered  intravenously  in  addition  to  statin  treatment
48].  The  development  of  this  drug  is  advancing  with  subcu-
aneous  administration.
afety of monoclonal antibodies targeting
CSK9
verall,  the  mAbs  tested  so  far  have  been  generally  safe  and
ell  tolerated,  with  no  major  safety  issues  from  completed
hase  I  and  II  studies.  In  each  of  the  phase  I  studies  for
lirocumab  and  evolocumab,  no  serious  adverse  events  were
eported  and  no  evidence  of  drug-related  adverse  events
as  observed  [35,39].
In  all  of  the  phase  II  studies,  alirocumab  was  generally
ell  tolerated  over  the  treatment  period  (8—12  weeks).
njection-site  reactions  were  the  most  common  adverse
vents  in  two  of  the  phase  II  trials  but  were  generally  mild
n  severity  and  transient.  However,  in  the  phase  II  study
ssessing  alirocumab  for  treatment  of  FH  [38],  one  patient
n  the  300  mg  dose  Q4W  group  discontinued  treatment  after
t
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he  ﬁrst  dose  due  to  injection-site  reaction  and  generalized
ruritus.  In  another  phase  II  trial  [37],  one  patient  receiving
torvastatin  80  mg  plus  alirocumab  150  mg  Q2W  discontin-
ed  treatment  due  to  a  hypersensitivity  reaction  and  rash
ccurring  12  days  after  the  second  injection  of  mAb.  There
as  a  single  case  of  cutaneous  leukocytoclastic  vasculitis
eported  in  one  patient,  9  days  after  initiation  of  alirocumab
00  mg  [36].  The  patient  responded  rapidly  to  withdrawal  of
he  drug  and  initiation  of  steroid  therapy.
Evolocumab  was  also  generally  well  tolerated  throughout
he  phase  II  trials,  with  a  similar  incidence  of  drug-related
dverse  events  across  treatment  groups  and  no  evidence  of
 relationship  between  the  incidence  of  any  adverse  event
nd  evolocumab  dose  [40—43].  Small  numbers  of  serious
dverse  events  occurred  but  none  was  considered  related
o  the  treatment.  Injection-site  reactions  were  generally
nfrequent  and  mild.  In  the  speciﬁc  trial  conducted  in  statin-
ntolerant  patients  [43], myalgia  was  the  most  common
reatment-emergent  adverse  event,  but  the  frequency  was
ow  (3%  in  the  placebo,  evolocumab  350  mg  and  420  mg
roups;  20%  in  the  evolocumab  420  mg/ezetimibe  group);
wo  patients  in  the  evolocumab  350  mg  group  had  creatine
inase  concentrations  greater  than  10  times  the  upper  nor-
al  limit  during  the  study.
Finally,  antibodies  against  alirocumab  and  evolocumab
ere  detected  at  low  titre  in  some  patients.  The  use  of
ully  human  mAbs,  such  as  alirocumab  and  evolocumab,  will
educe  the  risk  of  immunosensitivity  reactions  [49].
CSK9 inhibition with mAbs: evidence to
ate
urrent  data  indicate  that  a  fully  human  mAb  target-
ng  PCSK9  is  very  effective  at  lowering  concentrations  of
therogenic  lipoproteins,  with  signiﬁcant  decreases  in  LDL-
,  apoB,  non-HDL-C  and  also  Lp(a)  concentrations.  So  far,
fﬁcacy  has  been  demonstrated  in  addition  to  statins  in
ypercholesterolaemic  patients  with  and  without  FH,  in
atients  intolerant  to  statin  therapy  and  in  monotherapy.
n  additive  effect  between  a  PCSK9  inhibitor  and  ezetimibe
as  been  observed  for  patients  with  statin  intolerance.
Current  data  also  have  not  revealed  potential  on-target
ffects  of  blocking  PCSK9.  It  can  be  expected  that  mAbs
argeting  PCSK9  will  exhibit  fewer  side  effects  than  those
ssociated  with  maximum  statin  doses.  No  short-term  (12-
eek)  safety  issues  have  emerged  from  phase  II  trials  and
he  mAbs  tested  so  far  have  been  well  tolerated,  apart  from
ild  injection-site  reactions.
CSK9 inhibition: future perspectives
 number  of  important  questions  will  need  to  be  resolved
efore  the  approval  of  these  new  agents.  Long-term  efﬁcacy
nd  safety  trials  are  critical,  as  patients  will  probably  need
ife-long  treatment.  Even  if  anti-drug  antibodies  were  rare
n  phase  II  trials,  experience  with  other  mAbs  suggests  that
he  development  of  anti-drug  antibodies  could  reduce  clin-
cal  efﬁcacy  and  increase  the  incidence  of  adverse  events
49]. Two  large  phase  III  programmes  are  ongoing:  the
ROFICIO  programme  with  evolocumab;  and  the  ODYSSEY
DM
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programme  with  alirocumab.  Systematic  monitoring  of  anti-
body  development  and  adverse  events  will  be  needed  in
these  programmes.  Indeed,  while  genetic  PCSK9  deﬁciency
appears  safe,  this  may  not  be  relevant  for  mAb-based  sup-
pression  of  PCSK9  protein  in  individuals  with  genetically
normal  PCSK9.  The  safety  of  other  mAbs  and  siRNA-based
therapies  against  PCSK9  is  still  unknown.
As  suggested  by  the  reduced  incidence  of  events  in
healthy  patients  with  PCSK9  LOF  mutations,  the  cardio-
vascular  beneﬁt  in  relation  to  the  lowering  effect  of
atherogenic  lipoproteins  will  need  to  be  evaluated  in  speciﬁc
cardiovascular  outcome  trials.  Two  trials  —  FOURIER  with
evolocumab  and  ODYSSEY-OUCOMES  with  alirocumab  —  are
ongoing.
Additional  studies  will  also  be  needed  to  obtain  a  bet-
ter  understanding  of  the  physiological  role  of  PCSK9  and
the  effect  of  PCSK9  inhibition  in  other  populations,  such
as  patients  with  mixed  hyperlipidaemia,  diabetes  or  renal
impairment.
Moreover,  the  place  of  PSCK9  inhibitors  needs  to  be
deﬁned  in  comparison  with  other  strategies  that  are  either
available  or  under  development  to  reduce  the  residual  risk
linked  to  atherogenic  lipoproteins.  Undoubtedly,  a  PCSK9
inhibitor  combined  with  statin  therapy  will  be  more  effec-
tive  than  ezetimibe  and  resins  in  terms  of  LDL-C  lowering.
The  use  of  a  PCSK9  inhibitor  combined  with  a  low  statin  dose
also  seems  an  attractive  strategy  to  avoid  the  side  effects
associated  with  high  statin  doses.  The  statin-fenoﬁbrate
combination  therapy  is  only  useful  for  high-risk  patients  with
high  triglycerides  and  low  HDL-C  on  statin  therapy.  For  this
speciﬁc  category  of  patients,  the  efﬁcacy  of  PCSK9  inhibi-
tion  still  needs  to  be  established.  Among  the  new  classes
of  agents  that  reduce  LDL-C  under  development,  the  use
of  lomitapide  (a  microsomal  transfer  protein  inhibitor)  and
mipomersen  (an  ApoB  antisense  oligonucleotide)  will  be
limited  to  the  rare  population  of  patients  with  homozy-
gous  FH,  while  the  putative  beneﬁt  of  new  cholesteryl  ester
transfer  protein  inhibitors,  such  as  anacetrapib  and  evace-
trapib,  remains  controversial.
Among  the  candidate  populations  for  PCSK9  inhibition,
heterozygous  FH  should  be  considered  as  a  priority.  High-
risk  patients  with  documented  statin  intolerance  are  also
candidates  for  PCSK9  inhibition.  Other  medical  needs  are
high-risk  patients  not  at  goal  on  maximum  lipid-lowering
therapy,  but  the  cost/beneﬁt  ratio  will  be  an  important
issue.
Conclusion
PCSK9  is  a  key  player  in  LDL  metabolism,  mainly  by  enhanc-
ing  degradation  of  LDLR  in  the  liver.  The  reduced  incidence
of  cardiovascular  disease  in  patients  with  PCSK9  LOF  muta-
tions  provides  a  strong  rationale  for  the  development  of
PCSK9  inhibitors.  The  inhibition  of  PCSK9  is  the  most  attrac-
tive  new  approach  to  reducing  atherogenic  lipoproteins  and
enhancing  the  efﬁcacy  of  statins.  Phase  II  trials  have  shown
that  fully  human  mAbs  are  effective  and  well  tolerated.  The
ongoing  phase  III  trials  will  determine  long-term  efﬁcacy,
safety  and  tolerability,  including  effect  on  cardiovascular
disease.
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